A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

This study is testing a combination of pembrolizumab (an immunotherapy drug) with gemcitabine and cisplatin (chemotherapy) given both before and after surgery for patients with intrahepatic cholangiocarcinoma — a cancer of the bile ducts inside the liver — that may be surgically removable. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of intrahepatic cholangiocarcinoma or biliary adenocarcinoma - Your tumor is potentially resectable (operable) as assessed by a surgeon - Your tumor is measurable by standard imaging criteria (RECIST 1.1) - Your organ function (kidney, liver, blood counts) is adequate for chemotherapy **You may NOT be eligible if...** - Your cancer has spread to distant organs, making curative surgery impossible - You have had prior systemic chemotherapy or immunotherapy for this cancer - You have autoimmune disease or are on immune-suppressing medications - You have serious infections or other conditions that make treatment unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.